These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 12906005

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Proteasome inhibitors in the treatment of cancer.
    Golab J.
    Drug Discov Today; 2003 Jul 01; 8(13):575. PubMed ID: 12850331
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecule of the month. Bortezomib.
    Drug News Perspect; 2003 Jun 01; 16(5):324. PubMed ID: 12942163
    [No Abstract] [Full Text] [Related]

  • 8. Recent advances in the identification and development of 20S proteasome inhibitors.
    García-Echeverría C.
    Mini Rev Med Chem; 2002 Jun 01; 2(3):247-59. PubMed ID: 12370066
    [Abstract] [Full Text] [Related]

  • 9. The proteasome, a new target for cancer therapy.
    Gillessen S, Groettup M, Cerny T.
    Onkologie; 2002 Dec 01; 25(6):534-9. PubMed ID: 12566898
    [Abstract] [Full Text] [Related]

  • 10. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
    Mitra AP.
    IDrugs; 2009 Jun 01; 12(6):339-41. PubMed ID: 19517310
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. American society of clinical oncology - 45th annual meeting. Part 1.
    Gale S.
    IDrugs; 2009 Jul 01; 12(7):401-3. PubMed ID: 19579154
    [No Abstract] [Full Text] [Related]

  • 13. American society of clinical oncology - 45th annual meeting. Part 2.
    Lakeram M, Kibble A.
    IDrugs; 2009 Jul 01; 12(7):404-8. PubMed ID: 19579155
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antitumor pharmacology -- quo vadis?
    Bailly C, Barret JM, Kruczynski A.
    Curr Med Chem Anticancer Agents; 2004 Sep 01; 4(5):389-91. PubMed ID: 15379689
    [Abstract] [Full Text] [Related]

  • 17. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
    Dou QP, Smith DM, Daniel KG, Kazi A.
    Prog Cell Cycle Res; 2003 Sep 01; 5():441-6. PubMed ID: 14593738
    [Abstract] [Full Text] [Related]

  • 18. American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
    Erlich R, Durrance A.
    IDrugs; 2003 Jul 01; 6(7):623-4. PubMed ID: 12906003
    [No Abstract] [Full Text] [Related]

  • 19. MLN-519. Millennium/PAION.
    Di Napoli M, Papa F.
    Curr Opin Investig Drugs; 2003 Mar 01; 4(3):333-41. PubMed ID: 12735235
    [Abstract] [Full Text] [Related]

  • 20. Assays for proteasome inhibition.
    Elliott PJ, Soucy TA, Pien CS, Adams J, Lightcap ES.
    Methods Mol Med; 2003 Mar 01; 85():163-72. PubMed ID: 12710207
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.